Related Experiment Videos
Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria
V Gordeuk1, P Thuma, G Brittenham
1Case Western Reserve University School of Medicine, Cleveland, OH.
Insights
Iron chelation with deferoxamine may improve outcomes for children with cerebral malaria. This treatment appears to speed parasite clearance and enhance recovery from deep coma, though overall mortality rates were similar in the study.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Cerebral malaria, a severe Plasmodium falciparum complication in children, has high mortality rates (15-50%) despite antimalarial drugs.
- Standard treatment for cerebral malaria includes antimalarial therapy, but recovery can be prolonged.
Purpose of the Study:
- To investigate if combining iron chelation therapy with standard quinine treatment accelerates consciousness recovery in children with cerebral malaria.
- To evaluate the impact of deferoxamine on parasite clearance and mortality in pediatric cerebral malaria.
Main Methods:
- A randomized, double-blind, placebo-controlled trial involving 83 Zambian children under six with cerebral malaria.
- Patients received either intravenous deferoxamine or a placebo for 72 hours, alongside standard quinine and sulfadoxine-pyrimethamine therapy.
- Outcomes assessed included time to recovery of full consciousness, parasite clearance, and mortality, analyzed using Cox proportional-hazards regression.
Main Results:
- Deferoxamine showed a trend towards faster recovery of consciousness (median 20.2 vs. 43.1 hours), but this was not statistically significant overall (P = 0.38).
- In patients with deep coma, deferoxamine significantly increased the rate of consciousness recovery (2.2-fold, P = 0.03) and reduced median recovery time (68.2 to 24.1 hours).
- Iron chelation therapy with deferoxamine significantly accelerated parasite clearance (2.0-fold, P < 0.001) compared to placebo. Mortality rates were similar between groups (17% vs. 22%, P = 0.52).
Conclusions:
- Iron chelation therapy, specifically with deferoxamine, may be a beneficial adjunct treatment for pediatric cerebral malaria.
- Deferoxamine shows potential in hastening parasite clearance and improving neurological recovery, particularly in severe cases of cerebral malaria.
- Further research may explore optimal iron chelation strategies to reduce morbidity and mortality in cerebral malaria.
Background:
Cerebral malaria is a severe complication of Plasmodium falciparum infection in children, with a mortality rate of 15 to 50 percent despite antimalarial therapy.
Methods:
To determine whether combining iron chelation with quinine therapy speeds the recovery of consciousness, we conducted a randomized, double-blind, placebo-controlled trial of the iron chelator deferoxamine in 83 Zambian children with cerebral malaria. To be enrolled, patients had to be less than six years old, have P. falciparum parasitemia, have normal cerebrospinal fluid without evidence of bacterial infection, and be in a coma from which they could not be aroused. Deferoxamine (100 mg per kilogram of body weight per day, infused intravenously for 72 hours) or placebo was added to standard therapy with quinine and sulfadoxine-pyrimethamine. The time to the recovery of full consciousness, time to parasite clearance, and mortality were examined with Cox proportional-hazards regression analysis.
Results:
The rate of recovery of full consciousness among the 42 patients given deferoxamine was 1.3 times that among the 41 given placebo (95 percent confidence interval, 0.7 to 2.3); the median time to recovery was 20.2 hours in the deferoxamine group and 43.1 hours in the placebo group (P = 0.38). Among 50 patients with deep coma, the rate of recovery of full consciousness was increased 2.2-fold with deferoxamine (95 percent confidence interval, 1.1 to 4.7), decreasing the median recovery time from 68.2 to 24.1 hours (P = 0.03). Among 69 patients for whom data on parasite clearance were available, the rate of clearance with deferoxamine was 2.0 times that with placebo (95 percent confidence interval, 1.2 to 3.6). Among all 83 patients, mortality was 17 percent in the deferoxamine group and 22 percent in the placebo group (P = 0.52).
Conclusions:
Iron chelation therapy may hasten the clearance of parasitemia and enhance recovery from deep coma in cerebral malaria.